RSS-Feed abonnieren
DOI: 10.1055/s-0031-1296419
Pharmacokinetics and Comparative Bioavailability Study of Two Clarithromycin Suspensions Following Administration of a Single Oral Dose to Healthy Volunteers
Publikationsverlauf
Publikationsdatum:
13. Dezember 2011 (online)
![](https://www.thieme-connect.de/media/amf/200908/lookinside/thumbnails/10.1055-s-0031-1296419-1.jpg)
Abstract
The aim of the present study was to compare the pharmacokinetics and bioavailability of two commercial brands of clarithromycin (CAS 81103-11-9) suspensions in healthy male Iranian volunteers. In an open label, single-dose, randomized study with a crossover design an equivalent 500-mg clarithromycin suspension was given orally to each of 24 subjects as a single dose on two treatment days. The treatment periods were separated by a one-week washout period. Blood samples were drawn at different time points and the separated plasma was kept frozen at −20 °C for subsequent analysis. The plasma concentrations of the drug were analyzed by a rapid and sensitive HPLC method with UV detection.
Mean maximum serum concentrations of 2 256.5 ± 590.1 ng/mL and 2 840.2 ± 717.5 ng/mL were obtained for the test and reference formulation, respectively. The AUC0–infinity of clarithromycin was on average 45 008.7 ± 10 989.9 ng · h/mL for the test and 45 221.3 ± 2155.7 ng h/mL for the reference formulation. The calculated 90% confidence intervals for the ratio of Cmax (81.98–94.26%), (91.6–109.15%) and
(93.08–110.85%) values for the test and reference products were all within the 85–120% interval proposed by the FDA and EMEA. Therefore the clarithromycin suspension of the test and reference formulations are bioequivalent in terms of rate and extent of absorption.
-
References
- 1 Guay DR, Gustavson LE, Devcich KJ, Zhang J, Cao G, Olson CA. Pharmacokinetics and tolerability of extended-release clarithromycin. Clin Ther. 2001; 23 (4) 566-77
- 2 Nash KA. Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38). Anti-microb Agents Chemother. 2003; 47 (10) 3053-60
- 3 Andini N, Nash KA. Intrinsic macrolide resistance of the Mycobacterium tuberculosis complex is inducible. Antimi-crob Agents Chemother. 2006; 50 (7) 2560-2
- 4 Brown BA, Wallace Jr RJ. Onyi GO. Activities of clarithromycin against eight slowly growing species of nontuberculous mycobacteria, determined by using a broth microdilution MIC system. Antimicrob Agents Chemother. 1992; 36 (9) 1987-90
- 5 Fernandes PB, Hardy DJ, McDaniel D, Hanson CW, Swan-son RN. In vitro and in vivo activities of clarithromycin against Mycobacterium avium. Antimicrob Agents Chemother. 1989; 33 (9) 1531-4
- 6 Mor N, Esfandiari A. Synergistic activities of clarithromycin and pyrazinamide against Mycobacterium tuberculosis in human macrophages. Antimicrob Agents Chemother. 1997; 41 (9) 2035-6
- 7 Sweetman SC. Martindale The complete Drug Reference. London: The Pharmaceutical Press; 2007.
- 8 Ferrero JL, Bopp BA, Marsh KC, Quigley SC, Johnson MJ, Anderson DJ, Lamm JE, Tolman KG, Sanders SW, Cava-naugh JH et al Metabolism and disposition of clarithromycin in man. Drug Metab Dispos. 1990; 18 (4) 441-6
- 9 Guay DR, Craft JC. Overview of the pharmacology of clarithromycin suspension in children and a comparison with that in adults. Pediatr Infect Dis J. 1993; 12 (12 Suppl 3) S106-11
- 10 Amini H, Ahmadiani A. Sensitive determination of clarithromycin in human plasma by high-performance liquid chromatography with spectrophotometric detection. J Chromatogr B Analyt Technol Biomed Life Sci. 2005; 817 (2) 193-7
- 11 Zakeri-Milani P, Valizadeh H, Islambulchilar Z. Comparative bioavailability study of two cefixime formulations administered orally in healthy male volunteers. Arzneimittelforschung. 2008; 58 (2) 97-100
- 12 Guidance for industry, bioavailability and bioequivalence studies for orally administered drug products; General considerations. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Reserch (CDER), July 2002 BP.